Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on addiction treatment therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
CEO Cary Claiborne will represent Adial at the conference. The company's presentation will be available on-demand to registered attendees starting September 9, 2024, at 7:00 AM Eastern Time. Investors can access the presentation webcast through the conference platform or Adial's investor relations website.
Additionally, Adial's management team will be conducting one-on-one meetings with qualified investors throughout the conference. Interested parties can request meetings by contacting adil@crescendo-ir.com.
Adial Pharmaceuticals (NASDAQ: ADIL), una compagnia biofarmaceutica in fase clinica focalizzata su terapie per il trattamento delle dipendenze, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. L'evento si terrà dal 9 all'11 settembre 2024 presso il Lotte New York Palace Hotel a New York City.
Il CEO Cary Claiborne rappresenterà Adial alla conferenza. La presentazione dell'azienda sarà disponibile on-demand per i partecipanti registrati a partire dalle 7:00 AM Eastern Time del 9 settembre 2024. Gli investitori possono accedere alla trasmissione della presentazione tramite la piattaforma della conferenza o il sito web delle relazioni con gli investitori di Adial.
Inoltre, il team di gestione di Adial condurrà incontri one-to-one con investitori qualificati durante tutta la conferenza. Le parti interessate possono richiedere incontri contattando adil@crescendo-ir.com.
Adial Pharmaceuticals (NASDAQ: ADIL), una empresa biofarmacéutica en etapa clínica centrada en terapias para el tratamiento de adicciones, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento se llevará a cabo del 9 al 11 de septiembre de 2024 en el Lotte New York Palace Hotel en la ciudad de Nueva York.
El CEO Cary Claiborne representará a Adial en la conferencia. La presentación de la empresa estará disponible bajo demanda para los asistentes registrados a partir de las 7:00 AM, hora del Este, del 9 de septiembre de 2024. Los inversores pueden acceder a la webcast de la presentación a través de la plataforma de la conferencia o del sitio web de relaciones con inversores de Adial.
Además, el equipo directivo de Adial realizará reuniones uno a uno con inversores calificados durante toda la conferencia. Las partes interesadas pueden solicitar reuniones contactando a adil@crescendo-ir.com.
Adial Pharmaceuticals (NASDAQ: ADIL)는 중독 치료 요법에 중점을 둔 임상 단계의 제약 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여할 것이라고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕시의 Lotte New York Palace Hotel에서 개최됩니다.
CEO Cary Claiborne가 컨퍼런스에서 Adial을 대표할 것입니다. 회사의 발표는 2024년 9월 9일 오전 7시 (동부 표준시)부터 등록된 참석자들에게 주문형으로 제공됩니다. 투자자들은 컨퍼런스 플랫폼이나 Adial의 투자자 관계 웹사이트를 통해 발표 웹캐스트에 접근할 수 있습니다.
추가로, Adial의 경영 팀은 컨퍼런스 전체에 걸쳐 자격을 갖춘 투자자들과 일대일 회의를 진행할 예정입니다. 관심 있는 분들은 adil@crescendo-ir.com으로 회의를 요청할 수 있습니다.
Adial Pharmaceuticals (NASDAQ: ADIL), une entreprise biopharmaceutique en phase clinique axée sur les thérapies de traitement de la dépendance, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement se déroulera du 9 au 11 septembre 2024 au Lotte New York Palace Hotel à New York.
Le CEO Cary Claiborne représentera Adial lors de la conférence. La présentation de l'entreprise sera disponible à la demande pour les participants enregistrés à partir du 9 septembre 2024 à 7h00, heure de l'Est. Les investisseurs pourront accéder à la diffusion de la présentation via la plateforme de la conférence ou le site Web des relations avec les investisseurs d'Adial.
De plus, l'équipe de direction d'Adial mènera des réunions en tête-à-tête avec des investisseurs qualifiés tout au long de la conférence. Les parties intéressées peuvent demander des réunions en contactant adil@crescendo-ir.com.
Adial Pharmaceuticals (NASDAQ: ADIL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien zur Behandlung von Sucht spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investmentkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet vom 9. bis 11. September 2024 im Lotte New York Palace Hotel in New York City statt.
CEO Cary Claiborne wird Adial auf der Konferenz vertreten. Die Präsentation des Unternehmens wird ab 9. September 2024, 7:00 Uhr Eastern Time für registrierte Teilnehmer on-demand verfügbar sein. Investoren können über die Konferenzplattform oder die Investor-Relations-Website von Adial auf die Präsentation zugreifen.
Darüber hinaus wird das Management-Team von Adial Einzelgespräche mit qualifizierten Investoren während der gesamten Konferenz führen. Interessierte Parteien können Meetings anfordern, indem sie adil@crescendo-ir.com kontaktieren.
- None.
- None.
GLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
Adial’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024 at 7:00 AM Eastern Time. A webcast of the Company’s presentation can also be accessed at https://journey.ct.events/view/71ccecd3-b96e-47f9-8bff-a7f47811f1db and on the investor relations section of company Adial’s website at https://www.adial.com/investors/.
Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference in New York City. To request a meeting, please contact adil@crescendo-ir.com.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Forward-Looking Statements
This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding reporting topline results from the pharmacokinetics study of AD04 during the fourth quarter of 2024, the study satisfying a requirement of the FDA guidance the Company received as well as aiding in optimizing the study design for the planned Phase 3 clinical trial of AD04, Boudicca Dx ensuring compliance with FDA guidelines, receiving input from the FDA on the Company’s CDx plan for the US assisting in clinical success as well as aiding in the Company’s next interaction with the FDA on its Phase 3 trial, taking the essential next steps to provide the Company with the greatest probability of success during the Phase 3 trial while expanding potential partner opportunities, reporting the pharmacokinetic study results during the fourth quarter and swiftly commencing the Company’s Phase 3 trial of AD04, existing cash and cash equivalents funding operating expenses into the second half of 2025 based on current commitments and development plans and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: ADIL@crescendo-ir.com
FAQ
When and where is Adial Pharmaceuticals (ADIL) presenting at the H.C. Wainwright Global Investment Conference?
How can investors access Adial Pharmaceuticals' (ADIL) presentation at the H.C. Wainwright conference?
Who will be representing Adial Pharmaceuticals (ADIL) at the H.C. Wainwright conference in September 2024?
How can investors arrange one-on-one meetings with Adial Pharmaceuticals (ADIL) management at the H.C. Wainwright conference?
